Psychoneuroendocrinology
Volume 32, Issue 5 , Pages 480-492, June 2007

Neuroprotective effects of estradiol in hippocampal neurons and glia of middle age mice

  • Flavia Saravia

      Affiliations

    • Laboratory of Neuroendocrine Biochemistry, Instituto de Biología y Medicina Experimental, 1428 Buenos Aires, Argentina
    • Department of Human Biochemistry, Faculty of Medicine, University of Buenos Aires, 1033 Buenos Aires, Argentina
    • Corresponding Author InformationCorresponding author. Instituto de Biologia y Medicina Experimental, Obligado 2490, 1428 Buenos Aires, Argentina. Tel.: +541147832869x219; fax: +541147862564.
  • ,
  • Juan Beauquis

      Affiliations

    • Laboratory of Neuroendocrine Biochemistry, Instituto de Biología y Medicina Experimental, 1428 Buenos Aires, Argentina
  • ,
  • Luciana Pietranera

      Affiliations

    • Laboratory of Neuroendocrine Biochemistry, Instituto de Biología y Medicina Experimental, 1428 Buenos Aires, Argentina
    • Department of Human Biochemistry, Faculty of Medicine, University of Buenos Aires, 1033 Buenos Aires, Argentina
  • ,
  • Alejandro F. De Nicola

      Affiliations

    • Laboratory of Neuroendocrine Biochemistry, Instituto de Biología y Medicina Experimental, 1428 Buenos Aires, Argentina
    • Department of Human Biochemistry, Faculty of Medicine, University of Buenos Aires, 1033 Buenos Aires, Argentina

Received 21 October 2006; received in revised form 23 January 2007; accepted 1 February 2007.

Summary 

During aging the hippocampus experiences structural, molecular, and functional alterations. Protection from age-related disorders is provided by several factors, including estrogens. Since aging defects start at middle age, we studied if 17 β-estradiol (E2) protected the hippocampus at this age period. Middle age (10–12 month old) male C57Bl/6 mice were implanted sc with E2 (15μg) or cholesterol pellets. Ten days afterwards they received bromodeoxyuridine (BrdU) 4 and 2h before killing to study cell proliferation in the dentate gyrus (DG). A pronounced depletion of BrdU+cells in the DG was found in cholesterol-treated middle age mice, accompanied by astrocytosis, and by neuronal loss in the hilus. Middle age mice receiving E2 showed increased number of BrdU+cells while the other parameters were remarkably attenuated. When steroid treatment was prolonged for 2 months to study migration of cells in the granular layer of the DG, cell migration was unaffected by E2. However, E2-treated middle age mice presented higher cell density and increased staining for doublecortin, a marker for differentiating neurons. Thus, from the three basic steps of adult neurogenesis (proliferation, migration, and differentiation), E2 stimulated progenitor proliferation—even after long exposure to E2 studied by Ki67 immunocytochemistry—and differentiation towards a neuronal lineage. This result, in conjunction with recovery from other aging indicators as increased deposits of the aging pigment lipofuscin in DG cells, loss of hilar neurons and astrocytosis supports a wide range protection of hippocampal function of middle age mice by estrogenic hormones.

Keywords: Brain aging, Dentate gyrus, Neurogenesis, Estradiol, Neuroprotection, 5-bromo-2′-deoxyuridine (BrdU), Glial fibrillary acidic protein (GFAP), Hilar neurons, Lipofuscin, doublecortin, Ki67

Abbreviations: E2, 17β estradiol, BrdU, bromodeoxyuridine, DG, dentate gyrus, SGZ, subgranular zone, DCX, doublecortin, GCL, granular cell layer, HPA, hypothalamic–pituitary–adrenal, GFAP, glial fibrillary acidic protein, MA, middle age, chol, cholesterol

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0306-4530(07)00056-X

doi:10.1016/j.psyneuen.2007.02.012

Psychoneuroendocrinology
Volume 32, Issue 5 , Pages 480-492, June 2007